Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$26.74 USD
-0.77 (-2.80%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $26.75 +0.01 (0.04%) 6:42 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.74 USD
-0.77 (-2.80%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $26.75 +0.01 (0.04%) 6:42 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe
by Zacks Equity Research
Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval
by Zacks Equity Research
Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
by Zacks Equity Research
Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.
Here's What Could Help Bicycle Therapeutics PLC Sponsored ADR (BCYC) Maintain Its Recent Price Strength
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Bicycle Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Bicycle Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Has Bicycle Therapeutics PLC Sponsored (BCYC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BCYC) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for March 16th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 16th.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Bicycle Therapeutics PLC Sponsored (BCYC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BCYC) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for March 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 13th